Personalizing Anti-Cancer Treatment from Genetic and Pharmacokinetic Perspective UITNO

206 Pages·2016·8.31 MB·English

UITNODIGING
voor het bijwonen van de openbare
verdediging van het proefschrif
Personalizing Ant-Cancer Treatment from Genetc
Personalizing Ant-Cancer
and Pharmacokinetc Perspectve
Treatment from Genetc and
Pharmacokinetc Perspectve
woensdag 15 februari 2017
13.30 uur
Sander Bins Na afoop van de verdediging
bent u van harte uitgenodigd
voor de recepte
Professor Andries Queridozaal
Erasmus MC faculteit
Onderwijscentrum
Wytemaweg 80, Roterdam
Sander Bins
Ferdinand Bolstraat 29
3583 AP Utrecht
Personalizing Anti-Cancer Treatment from Genetic and
Pharmacokinetic Perspective

Het personaliseren van de behandeling tegen kanker vanuit genetisch en farmacokinetisch
oogpunt

Sander Bins
Personalizing Anti-Cancer Treatment from Genetic and
Pharmacokinetic Perspective

Het personaliseren van de behandeling tegen kanker vanuit genetisch en farmacokinetisch
oogpunt

Proefschrift

ter verkrijging van de graad van doctor aan de
Erasmus Universiteit Rotterdam

op gezag van de

rector magnificus

Prof.dr. H.A.P. Pols

en volgens besluit van het College voor Promoties.

De openbare verdediging zal plaatsvinden op

Woensdag 15 februari 2017 om 13.30 uur

Sander Bins

geboren te Voorburg

Colofon

ISBN: 978-94-6299-502-4
Printed by: Ridderprint BV

© Sander Bins, 2016
Allrights reserverd. No parts of this book may be reproduced or transmitted, in any form
or by any means, without writen permision of the author.
P e r d s o n a l i z i n g A n t i - C a n c e r T r e a t m e n t f r o m G e n e t i c a n
Pharmacokinetic Perspective

Het personaliseren van de behandeling tegen kanker vanuit genetisch en farmacokinetisch
oogpunt

Proefschrift

ter verkrijging van de graad van doctor aan de
Erasmus Universiteit Rotterdam

op gezag van de

rector magnificus

Prof.dr. H.A.P. Pols

en volgens besluit van het College voor Promoties.

De openbare verdediging zal plaatsvinden op

Woensdag 15 februari 2017 om 13.30 uur

Sander Bins

geboren te Voorburg

Colofon

ISBN: 978-94-6299-502-4
Printed by: Ridderprint BV

© Sander Bins, 2016
Allrights reserverd. No parts of this book may be reproduced or transmitted, in any form
or by any means, without writen permision of the author.
Promotiecommissie

Promotoren: Prof.dr. S. Sleijfer Hoe verder men keek,
Prof.dr. A.H.J. Mathijssen hoe groter het leek.
J.A. Deelder
Overige leden: Prof.dr. R.H.N. van Schaik
Prof.dr. A.D.R. Huitema
Prof.dr. E.E. Voest
Promotiecomisie

Promotoren: Prof.dr. S. Sleijfer Hoe verder men keek,
Prof.dr. A.H.J. Mathijssen hoe groter het leek.
J.A. Deelder
Overige leden: Prof.dr. R.H.N. van Schaik
Prof.dr. A.D.R. Huitema
Prof.dr. E.E. Voest
Contents
Chapter 1 Introduction 9

Chapter 2 Implementation of a multicenter biobanking 17
collaboration for next-generation sequencing-based
biomarker discovery based on fresh frozen pre-
treatment tumor biopsies
Oncologist. 2016 Sep 23 [Epub ahead of print]

Chapter 3 The time to progression ratio: a new individualized 43
volumetric parameter for the early detection of clinical
benefit of targeted therapies
Ann. Oncol. 2016;27(8):1638-1643

Chapter 4 Conventional dosing of anticancer agents: precisely 61
wrong or just inaccurate?
Clin. Pharmacol. Ther. 2014;95(4):361-364

Chapter 5 Influence of OATP1B1 Function on the Disposition of 69
Sorafenib-β-D-Glucuronide
Submitted

Chapter 6 Polymorphisms in SLCO1B1 and UGT1A1 are 95
associated with sorafenib-induced toxicity
Pharmacogenomics 2016;17(14):1483-1490

Chapter 7 Prospective Analysis in GIST Patients on the Role of 111
Alpha-1 Acid Glycoprotein in Imatinib Exposure
Clin Pharmacokinet. 2016 Jul 26 [Epub ahead of print]

Chapter 8 Individualized pazopanib dosing: a prospective 125
feasibility study in cancer patients
Clin. Cancer Res. 2016;22(23):5738-5746

Chapter 9 Development and clinical validation of an LC-MS/MS 145
method for the quantification of pazopanib in DBS.
Bioanalysis. 2016;8(2):123-134

Chapter 10 Discussion 167

Chapter 11 Dutch summary 181

Appendices 187
Contents
Chapter 1 Introduction 9

Chapter 2 Implementation of a multicenter biobanking 17
collaboration for next-generation sequencing-based
biomarker discovery based on fresh frozen pre-
treatment tumor biopsies
Oncologist. 2016 Sep 23 [Epub ahead of print]

Chapter 3 The time to progression ratio: a new individualized 43
volumetric parameter for the early detection of clinical
benefit of targeted therapies
Ann. Oncol. 2016;27(8):1638-1643

Chapter 4 Conventional dosing of anticancer agents: precisely 61
wrong or just inaccurate?
Clin. Pharmacol. Ther. 2014;95(4):361-364

Chapter 5 Influence of OATP1B1 Function on the Disposition of 69
Sorafenib-β-D-Glucuronide
Submitted

Chapter 6 Polymorphisms in SLCO1B1 and UGT1A1 are 95
associated with sorafenib-induced toxicity
Pharmacogenomics 2016;17(14):1483-1490

Chapter 7 Prospective Analysis in GIST Patients on the Role of 111
Alpha-1 Acid Glycoprotein in Imatinib Exposure
Clin Pharmacokinet. 2016 Jul 26 [Epub ahead of print]

Chapter 8 Individualized pazopanib dosing: a prospective 125
feasibility study in cancer patients
Clin. Cancer Res. 2016;22(23):5738-5746

Chapter 9 Development and clinical validation of an LC-MS/MS 145
method for the quantification of pazopanib in DBS.
Bioanalysis. 2016;8(2):123-134

Chapter 10 Discussion 167

Chapter 11 Dutch summary 181

Appendices 187
CHAPTER 1

Introduction